Skip to main content
SpringerLink
Log in
Book cover

Radiobiology and Environmental Security pp 111–125Cite as

Molecular-Genetic Analysis of Genetic Predisposition to Myocardial Infarction and Comparison of Risk Factor Population Rates in Different Countries

  • Conference paper
  • First Online:

Abstract

Factor V Leiden and Protrombin G20210A mutations as well as some gene polymorphisms, such as Val34Leu of the coagulation factor XIII, 4G/5G of PAI-1 gene and Thr312Ala of fibrinogen alpha chain have been investigated as risk factors of myocardial infarction (MI). The methods of polymerase chain reaction (PCR) with specially designed allele specific primers were used to determine polymorphisms and mutations. DNA extracted from lymphocytes or dried bloodspots was used as matrix for PCR. Blood samples of 175 patients with acute myocardial infarction and 270 people of the control group were investigated. It was obtained that the rate of Thr312Ala heterozygotes among patients with myocardial infarction was 1.3 times as high as in the control group. The frequency of Factor V Leiden and G20210 mutations in patients with myocardial infarction was more than 2 times as high as in the control group. Leu/Leu genotype was shown to be responsible for risk of myocardial infarction development too (OR = 2.02). According to our data 4G/4G genotype of the PAI-1 gene may be predisposing to the myocardial infarction and 5G/5G one – protecting. Population frequencies of MI genetic risk factors in Belarus population have been established. The comparison of MI predisposition genotypes frequencies with the levels of this disease in different countries of Europe has been performed. We revealed a statistically significant positive correlation between the frequencies of MI morbidity and 4G/4G genotype. At the same time, there was no statistically significant correlation between frequencies of other risk factors and MI frequency. The obtained data allows conclusion that PAI-1 gene genotype 4G/4G is the most informative for evaluation of genetic predisposition to MI.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Antoniadi T, Hatzis T, Kroupis C, Economou-Petersen E, Petersen MB (1999) Prevalence of factor V Leiden, Prothrombin G20210A and MTHFR C677T mutations in a Greek population of blood donors. Am J Hematol 61:265–267

    Article  CAS  Google Scholar 

  2. Awidi A, Shannak M, Bseiso A, Kailani MAM, Anshasi B, Sakarneh N, Omar N (1999) High prevalence of factor V Leiden in healthy Jordanian Arabs. Thromb Haemost 81(4):582–584

    CAS  Google Scholar 

  3. Baranovskaya S, Kudinov S, Fomicheva E, Vasina V, Solovieva D, Khavinson V, Schwartz E (2006) Age as a risk factor for myocardial infarction in Leiden mutation carriers. Mol Genet Metab 84:155–157

    Google Scholar 

  4. Bereczky Z, Balogh E, Katona E, Pocsai Z, Czuriga I, Széles G, Kárpáti L, Ádány R, Édes I, Muszbek L (2007) Modulation of the risk of coronary sclerosis/myocardial infarction by the interaction between factor XIII subunit A Val34Leu polymorphism and fibrinogen concentration in the high risk Hungarian population. Thromb Res 120:567–573

    Article  CAS  Google Scholar 

  5. Bertina RM, Koeleman BPC, Koster T, Rosendal FR, Dirven RJ, de Ronde H (1994) Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369:64–67

    Article  CAS  Google Scholar 

  6. Blasiak J, Smolarz B (2000) Plasminogen activator inhibitor-1 (PAI-1) gene 4G/5G promoter polymorphism is not associated with breast cancer. Acta Biochim Pol 47:191–199

    CAS  Google Scholar 

  7. Boekholdt SM, Bijsterveld NR, Moons AH, Levi M, Büller HR, Peters RJ (2001) Genetic variation in coagulation and fibrinolytic proteins and their relation with acute myocardial infarction: a systematic review. Circulation 104:3063–3068

    Article  CAS  Google Scholar 

  8. Broni A, Feren G, Zadro R, Rukavina A (2005) Factor XIII Val34Leu polymorphism in Croatian population. Thromb Haemost 3(1):69–75

    Google Scholar 

  9. Camilleri RS (2004) 455G/A [beta]-fibrinogen gene polymorphism, factor V Leiden, prothrombin G20210A mutation and MTHFR C677T, and placental vascular complications. Blood Coagul Fibrinolysis 15:139–147

    Article  CAS  Google Scholar 

  10. Carter M, Catto AJ, Grant PJ (1999) Association of the α-fibrinogen Thr312Ala polymorphism with poststroke mortality in subjects with atrial fibrillation. Circulation 99:2423–2426

    CAS  Google Scholar 

  11. Catto A, Carter A, Ireland H, Bayston TA, Philippou H, Barrett J, Lane DA, Grant PJ (2004) Factor V Leiden gene mutation and thrombin generation in relation to the development of acute stroke. Arterioscler Thromb Vasc Biol 17:783–785

    Google Scholar 

  12. Coen D, Zadro R, Honovi L, Banfi L, Rukavina AS (2001) Prevalence and association of the factor V Leiden and prothrombin G20210A in healthy subjects and patients with venous thromboembolism. Croat Med J 42(4):488–492

    CAS  Google Scholar 

  13. Corral J, Iniesta JA (2000) Factor XIII Val34Leu polymorphism in primary intracerebral haemorrhage. Hematol J 1:269–273

    Article  CAS  Google Scholar 

  14. Curran JM, Evans A, Arveiler D, Luc G, Ruidavets JB, Humphries SE, Green FR (1998) The α-fibrinogen T/A312 polymorphism in the ECTIM study. Thromb Haemost 79:1057–1058

    CAS  Google Scholar 

  15. de Lange M, Snieder H, Ariëns RAS, Spector TD, Grant PJ (2004) The genetics of haemostasis: a twin study. Lancet 357:101–105

    Article  Google Scholar 

  16. de Lange M, Andrew T, Snieder H, Ge D, Futers TS, Standeven K, Spector TD, Grant PJ, Ariëns RAS (2006) Joint linkage and association of six single-nucleotide polymorphisms in the factor XIII-A subunit gene point to Val34Leu as the main functional locus. Arterioscler Thromb Vas Biol 26:1914–1919, 26

    Article  Google Scholar 

  17. Doggen CJ, Bertina RM, Cats VM, Reitsma PH, Rosendaal FR (1999) The 4G/5G polymorphism in the plasminogen activator inhibitor-1 gene is not associated with myocardial infarction. Thromb Haemost 82:115–120

    CAS  Google Scholar 

  18. Eriksson P, Kallin B, van ’t Hooft FM, Bavenholm P, Hamsten A (1995) Allele specific increase in basal transcription of the plasminogen activator inhibitor-1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA 92(6):1851–1855

    Article  CAS  Google Scholar 

  19. Frances F, Portoles O, Gabriel F, Corella D, Sorli JV, Sabater A (2006) Factor V Leiden (G1691A) and prothrombin-G20210A alleles among patients with deep venous thrombosis and in the general population from Spain. Rev Méd Chile 134(1):13–20

    Article  CAS  Google Scholar 

  20. Gialeraki A, Politou M, Rallidis L, Merkouri E, Markatos C, Kremastinos D, Travlou A (2008) Prevalence of prothrombotic polymorphisms in Greece. Genet Test 12:541–547

    Article  CAS  Google Scholar 

  21. Gonchar L, Mosse IB, Ivanov AA, Mosse NI, Mosse KA (2009) Association of the PAI-I polymorphism and Factor V Leiden mutation with genetic predisposition to myocardial infarction. Mol Appl Genet Proc 9:114–120

    Google Scholar 

  22. Gonchar L, Mosse IB, Ivanov AA, Mosse NI, Mosse KA (2009) Polymorphisms of clot formation genes and their role in myocardial infarction. Arterial Hypertens 15(4):466–469

    Google Scholar 

  23. Gusina AA, Gusina NB, Zatsepin IO, Baeshko AA, Naumchik IV (2007) The role of factor II and V mutations in the development of venous thrombosis in Belarusian citizens. Medicinskie novosti 5:85–88, In Russian

    Google Scholar 

  24. Herrmann FH, Salazar-Sanchez L, Schröder W, Grimm R, Schuster G, Jimenez-Arce G (2001) Prevalence of molecular risk factors FV Leiden, FV HR2, FII 20210G>A and MTHFR 677C>T in different populations and ethnic groups of Germany, Costa Rica and India. Int J Hum Genet 1:33–39

    Google Scholar 

  25. Hoekstra T, Geleijnse JM, Kluft C, Giltay EJ, Kok FJ, Schouten EG (2003) 4G/4G genotype of PAI-1 gene is associated with reduced risk of stroke in elderly. Stroke 34:2822–2828

    Article  CAS  Google Scholar 

  26. Holm J, Zöller B, Berntorp E, Erhardt L, Dahlbäck B (1996) Prevalence of factor V gene mutation amongst myocardial infarction patients and healthy controls is higher in Sweden than in other countries. J Intern Med 239(3):221–226

    Article  CAS  Google Scholar 

  27. Hong SH (2003) Genotype distribution of the mutations in the coagulation factor V gene in the Korean population: absence of its association with coronary artery disease. Korean J Biol Sci 7:255–259

    Article  CAS  Google Scholar 

  28. Iacoviello L, Di Castelnuovo A, De Knijff P, D’Orazio A, Amore C, Arboretti R, Kluft C, Donati MB (2000) Polymorphisms in the coagulation factor VII gene and the risk of myocardial infarction. N Engl J Med 338:79–85

    Article  Google Scholar 

  29. Irani-Hakime N, Tamim H, Kreidy R, Almawi WY (2000) The prevalence of factor V R506Q mutation-Leiden among apparently healthy Lebanese. Am J Hematol 65:45–49

    Article  CAS  Google Scholar 

  30. Izakovicová HL, Bucková D, Fassmann A, Benes P, Znojil V (2002) Plasminogen-activator-inhibitor-1 promoter polymorphism as a risk factor for adult periodontitis in non-smokers. Genes Immun 3:292–294

    Article  Google Scholar 

  31. Jood K, Ladenvall P, Tjärnlund-Wolf A, Ladenvall C, Andersson M, Nilsson S, Blomstrand C, Jern C (2005) Fibrinolytic gene polymorphism and ischemic stroke. Stroke 36:2077–2081

    Article  CAS  Google Scholar 

  32. Kalashnikova EA, Kokarovtseva SN, Kovalenko TF, Sirotkina OV, Sheidina AM, Zorilova IV (2006) The frequencies of mutations in Factor V (FV Leiden), Prothrombin (G20210A) and 5,10-methylentetrahydrofolate reductase (C677T) genes in Russians. Medicinskaya Genetika 7:68–72, In Russian

    Google Scholar 

  33. Komitopoulou A, Platokouki H, Kapsimali Z, Moschovi M, Kattamis A, Pergantou H, Aronis S (2006) Mutations and polymorphisms in genes affecting haemostasis components in children with thromboembolic events. Thromb Haemost 35:392–397

    CAS  Google Scholar 

  34. Larsen TB, Lassen JF, Brandslund I, Byriel L, Petersen JB, Norgaard-Pedersen B (1998) The Arg506Gln mutation (FV Leiden) among a cohort of 4188 unselected Danish newborns. Thromb Res 89(5):211–215

    Article  CAS  Google Scholar 

  35. Lee DH, Henderson PA, Blajchman MA (1996) Prevalence of factor V Leiden in a Canadian blood donor population. CMAJ 155:285–289

    CAS  Google Scholar 

  36. Leroyer C, Mercier B, Oger E, Chenu E, Abgrall J, Ferec C, Mottier D (1998) Prevalence of the 20210A allele of the prothrombin gene in venous thromboembolism patients. Thromb Haemost 80:49–51

    CAS  Google Scholar 

  37. Lucotte G, Mercier G (2001) Population genetics of factor V Leiden in Europe. Blood Cells Mol Dis 27:362–367

    Article  CAS  Google Scholar 

  38. Makowski GS, Davis EL, Aslanzadeh J, Hopfer SM (1995) Enhanced direct amplification of Guthrie card DNA following selective elution of PCR inhibitors. Nucleic Acids Res 23(18):3788–3789

    Article  CAS  Google Scholar 

  39. Mansilha A, Araujo F (2009) The association between the Val34Leu mutation in the factor XIII gene and deep venous thrombosis in young people. Dialnet 12:5–8

    Google Scholar 

  40. Margaglione M, Cappucci G, Colaizzo D, Giuliani N, Vecchione G, Grandone E, Pennelli O, Di Minno G (1998) The PAI-1 gene locus 4G/5G polymorphism is associated with a family history of coronary artery disease. Arterioscler Thromb Vasc Biol 18:152–156

    Article  CAS  Google Scholar 

  41. Middendorf K, Göhring P, Huehns TY, Seidel D, Steinbeck G, Nikol S (2004) Prevalence of resistance against activated protein c resulting from factor V Leiden is significantly increased in myocardial infarction: investigation of 507 patients with MI. Am Heart J 147(5):897–904

    Article  CAS  Google Scholar 

  42. Moller L, Kristensen TS (1991) Plasma fibrinogen and ischemic heart disease risk factors. Arterioscler Thromb 11(2):344–350

    Article  CAS  Google Scholar 

  43. Olafsson I, Hjaltadottir S, Onundarson PT, Porarinsdottir R, Haraldsdottir V (1998) Prevalence of factor VQ506 and prothrombin 20210 A mutations in an apparently healthy icelandic population and patients suffering from venous thrombosis. Thromb Haemost 79:684–685

    Google Scholar 

  44. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM (1996) A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 88:3698–3703

    CAS  Google Scholar 

  45. Rallidis S (2008) Factor XIII Val34Leu polymorphism and the risk of myocardial infarction. Thromb Haemost 99:1085–1089

    CAS  Google Scholar 

  46. Rees DC, Cox M, Clegg JB (2002) World distribution of factor V Leiden. Lancet 346:1133–1134

    Article  Google Scholar 

  47. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP (1995) Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 332(14):912–917

    Article  CAS  Google Scholar 

  48. Ridker PM, Miletich JP, Hennekens CH, Buring JE (1997) Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening. JAMA 277(16):1305–1307

    Article  CAS  Google Scholar 

  49. Rodeghiero F, Tosetto A (1999) Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism. Ann Intern Med 130:643–650

    CAS  Google Scholar 

  50. Rosen E, Renbaum P, Heyd J, Levy-Lahad E (1999) High frequency of factor V Leiden in a population of Israeli Arabs. Thromb Haemost 82:1768

    CAS  Google Scholar 

  51. Rosendaal R, Koster T, Vandenbroucke JP, Reitsma PH (1995) High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 85:1504–1508

    CAS  Google Scholar 

  52. Rosendaal FR, Doggen CJM, Zivelin A, Arruda VR, Aiach M, Siscovick DS, Hillarp A, Watzke HH, Bernardi F, Cumming AM, Preston FE, Reitsma PH (1998) Geographic distribution of the 20210G to A prothrombin variant. Thromb Haemost 79:706–708

    CAS  Google Scholar 

  53. Sadasivan C, Yee VC (2000) Interaction of the factor XIII activation peptide with thrombin. J Biol Chem 275:362–368

    Article  Google Scholar 

  54. Saksela O, Rifkin DB (1988) Cell-associated plasminogen activation:regulation and physiologic functions. Annu Rev Cell Biol 4:93–126

    Article  CAS  Google Scholar 

  55. Settin A, Dowaidar M, El-Baz R, Abd-Al-Samad A, El-Sayed I, Nasr M (2008) Frequency of factor V Leiden mutation in Egyptian cases with MI. Hematology 3(3):170–174

    Article  Google Scholar 

  56. Shafey M, Anderson JL, Scarvelis D, Doucette SP, Gagnon F, Wells PS (2007) Factor XIII Val34Leu variant and the risk of myocardial infarction: a meta-analysis. Thromb Haemost 97:635–641

    CAS  Google Scholar 

  57. WHO, Minsk (8 Feb 2010); http://www.euro.who.int

  58. Wiklund PG, Nilsson L, Ardnor SN, Eriksson P, Johansson L, Stegmayr B, Hamsten A, Holmberg D, Asplund K (2005) Cohorts replicated findings in two nested case-control studies based on independent plasminogen activator inhibitor-1 4G/5G polymorphism and risk of stroke. Stroke 36:1661–1665

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Genetics and Cytology at National Academy of Sciences of Belarus, Akademicheskaya str. 27, Minsk, 220072, Belarus

    Alexander Gonchar, Maxim Ameliyanovich, Kristina Zhur & Irma Mosse

  2. National Center of Research and Applied Medicine “Mother and Child”, Orlovskaya str. 66, Minsk, 220053, Belarus

    Konstantin Mosse

Authors
  1. Alexander Gonchar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maxim Ameliyanovich
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kristina Zhur
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Irma Mosse
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Konstantin Mosse
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Konstantin Mosse .

Editor information

Editors and Affiliations

  1. , Medical Physics, McMaster University, Main Street West 1280, Hamilton, L8S 4 K1, Canada

    Carmel E. Mothersill

  2. Joint Institute for Nuclear Research, Dubna, Moscow Region, 141980, Russian Federation

    Victoria Korogodina

  3. , Department of Medical Physics, McMaster University, Main Street West 1280, Hamilton, L8S 4K1, Canada

    Colin B. Seymour

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media B.V.

About this paper

Cite this paper

Gonchar, A., Ameliyanovich, M., Zhur, K., Mosse, I., Mosse, K. (2012). Molecular-Genetic Analysis of Genetic Predisposition to Myocardial Infarction and Comparison of Risk Factor Population Rates in Different Countries. In: Mothersill, C., Korogodina, V., Seymour, C. (eds) Radiobiology and Environmental Security. NATO Science for Peace and Security Series C: Environmental Security. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-1939-2_11

Download citation

Publish with us

Policies and ethics

Search

Navigation